TG Therapeutics, Inc. (TGTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$54.17+1.90%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge TG Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.4%

+10% or more+5%0%−5%−10% or less

2.86 → 2.87 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	269.51M
EPS	—	0.452
FY 2026 · Annual
product revenue	$890M–$905M	—
Revenue	About $950M	960.01M
EPS	—	1
FY 2027 · Annual
Revenue	—	1.32B
EPS	—	2.874

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
BRIUMVI U.S. net product revenue sustains above $194.8M quarterly	BRIUMVI expansion shows strong market demand.	Intact	BRIUMVI U.S. revenue drops below $150 million quarterly	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
BRIUMVI revenue grows to at least $892.5M in 2026	TG Therapeutics grows BRIUMVI revenue from $161.7M to $204.9M in 2026-Q1.	Intact	BRIUMVI revenue falls below $600 million in FY26	Revenue: $240.335M FY2026-Q2; GAAP. Published target: >= $892.5 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026240,335,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4506ef57-6301-4d0b-b853-4ea66caf494d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Total global revenue increased from $192.6 million in 2025-Q4 to $240.3 million in 2026-Q2, with BRIUMVI U.S. net product revenue rising from $182.7 million to $227.7 million over the same period. Management has consistently raised full-year 2026 revenue guidance, reflecting delivering growth trajectory. Delivery assessment Oct 24, 2026
Operating expenses stay near $350 million in 2026	Operating expenses target $350M for 2026 to control costs.	Intact	Operating expenses exceed $400 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 4 quarters. Management targets full year 2026 operating expenses of $350-400 million excluding non-cash compensation plus $100 million for subcutaneous BRIUMVI manufacturing. Operating income declined from $50.5 million in 2025-Q4 to $21.7 million in 2026-Q2, with R&D expenses rising to $95.3 million in 2026-Q2 from $41.2 million in 2025-Q4, indicating mixed progress on cost management. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.87

$3.28 → $2.87 · observed estimates

FY2027 revenue$1.32B

$1.27B → $1.32B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.28	$1,267,041,420	6 / 9
2026-07-25	$3.28	$1,292,245,230	6 / 8
2026-07-26	$3.04	$1,292,260,115	6 / 6
2026-07-27	$3.28	$1,292,245,230	6 / 8
2026-07-28	$3.28	$1,292,245,230	6 / 8
2026-07-29	$3.04	$1,292,260,115	6 / 6
2026-07-30	$3.28	$1,292,420,230	6 / 8
2026-07-31	$3.05	$1,292,435,115	6 / 6
2026-08-01	$3.05	$1,292,435,115	6 / 6
2026-08-02	$3.28	$1,292,420,230	6 / 8
2026-08-03	$3.05	$1,292,435,115	6 / 6
2026-08-04	$3.28	$1,292,420,230	6 / 8
2026-08-05	$3.15	$1,312,570,230	6 / 8
2026-08-06	$3.05	$1,292,435,115	6 / 6
2026-08-08	$2.96	$1,313,249,540	6 / 6
2026-08-09	$3.10	$1,313,272,150	6 / 8
2026-08-10	$3.10	$1,313,272,150	6 / 8
2026-08-12	$2.96	$1,313,249,540	6 / 6
2026-08-13	$2.96	$1,313,249,540	6 / 6
2026-08-14	$2.96	$1,313,249,540	6 / 6
2026-08-15	$2.96	$1,313,249,540	6 / 6
2026-08-16	$2.96	$1,313,249,540	6 / 6
2026-08-17	$2.96	$1,313,249,540	6 / 6
2026-08-18	$2.96	$1,313,249,540	6 / 6
2026-08-19	$2.96	$1,313,249,540	6 / 6
2026-08-20	$2.86	$1,318,061,895	6 / 6
2026-08-21	$2.86	$1,318,061,895	6 / 6
2026-08-22	$2.86	$1,318,061,895	6 / 6
2026-08-23	$2.86	$1,318,061,895	6 / 6
2026-08-24	$2.86	$1,318,061,895	6 / 6
2026-08-25	$2.86	$1,318,061,895	6 / 6
2026-08-26	$2.86	$1,318,061,895	6 / 6
2026-08-27	$2.86	$1,318,061,895	6 / 6
2026-08-28	$2.86	$1,318,061,895	6 / 6
2026-08-29	$2.86	$1,318,061,895	6 / 6
2026-08-30	$2.86	$1,318,061,895	6 / 6
2026-08-31	$2.86	$1,318,061,895	6 / 6
2026-09-01	$2.86	$1,318,061,895	6 / 6
2026-09-02	$2.86	$1,318,061,895	6 / 6
2026-09-03	$2.86	$1,318,061,895	6 / 6
2026-09-04	$2.86	$1,318,061,895	6 / 6
2026-09-05	$2.86	$1,318,061,895	6 / 6
2026-09-06	$2.86	$1,318,061,895	6 / 6
2026-09-07	$2.86	$1,318,061,895	6 / 6
2026-09-08	$2.86	$1,318,061,895	6 / 6
2026-09-09	$2.86	$1,318,061,895	6 / 6
2026-09-10	$2.86	$1,318,061,895	6 / 6
2026-09-11	$2.86	$1,318,061,895	6 / 6
2026-09-12	$2.86	$1,318,061,895	6 / 6
2026-09-13	$2.86	$1,318,061,895	6 / 6
2026-09-14	$2.86	$1,318,061,895	6 / 6
2026-09-15	$2.86	$1,318,061,895	6 / 6
2026-09-16	$2.86	$1,318,061,895	6 / 6
2026-09-17	$2.86	$1,318,061,895	6 / 6
2026-09-18	$2.86	$1,318,061,895	6 / 6
2026-09-19	$2.86	$1,318,061,895	6 / 6
2026-09-20	$2.86	$1,318,061,895	6 / 6
2026-09-21	$2.86	$1,318,061,895	6 / 6
2026-09-22	$2.86	$1,318,061,895	6 / 6
2026-09-23	$2.86	$1,318,061,895	6 / 6
2026-09-24	$2.86	$1,318,061,895	6 / 6
2026-09-25	$2.86	$1,318,061,895	6 / 6
2026-09-26	$2.86	$1,320,111,895	6 / 6
2026-09-27	$2.86	$1,320,111,895	6 / 6
2026-09-28	$2.86	$1,320,111,895	6 / 6
2026-09-29	$2.83	$1,321,111,895	6 / 6
2026-09-30	$2.83	$1,321,111,895	6 / 6
2026-10-01	$2.83	$1,321,111,895	6 / 6
2026-10-02	$2.83	$1,321,111,895	6 / 6
2026-10-03	$2.83	$1,321,111,895	6 / 6
2026-10-04	$2.83	$1,321,111,895	6 / 6
2026-10-05	$2.83	$1,321,111,895	6 / 6
2026-10-06	$2.83	$1,321,111,895	6 / 6
2026-10-07	$2.83	$1,321,111,895	6 / 6
2026-10-08	$2.83	$1,321,111,895	6 / 6
2026-10-09	$2.83	$1,321,111,895	6 / 6
2026-10-10	$2.83	$1,321,111,895	6 / 6
2026-10-11	$2.83	$1,321,111,895	6 / 6
2026-10-12	$2.83	$1,321,111,895	6 / 6
2026-10-13	$2.83	$1,321,111,895	6 / 6
2026-10-14	$2.83	$1,321,111,895	6 / 6
2026-10-15	$2.87	$1,321,111,895	6 / 6
2026-10-16	$2.87	$1,321,111,895	6 / 6
2026-10-17	$2.87	$1,321,111,895	6 / 6
2026-10-18	$2.87	$1,321,111,895	6 / 6
2026-10-19	$2.87	$1,321,111,895	6 / 6
2026-10-20	$2.87	$1,319,061,895	6 / 6
2026-10-21	$2.87	$1,319,061,895	6 / 6
2026-10-22	$2.87	$1,319,061,895	6 / 6
2026-10-23	$2.87	$1,319,061,895	6 / 6
2026-10-24	$2.87	$1,319,061,895	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	1	1
2026-06-01	7	1	1
2026-07-01	7	1	1
2026-08-01	7	0	1
2026-09-01	7	0	1
2026-10-01	7	0	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

BRIUMVI U.S. net product revenue sustains above $194.8M quarterlyDirect metric needs a verified mapping
BRIUMVI revenue grows to at least $892.5M in 2026Revenue: $240.335M
Operating expenses stay near $350 million in 2026Direct metric needs a verified mapping

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-22.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

TG Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-focused biotechnology business, with its current thesis centered on expanding BRIUMVI revenue and developing easier dosing options. The long-term thesis is intact, but earnings quality remains weak because the company is loss-making, and near-term execution risk is elevated.

What's priced into TG Therapeutics, Inc.

Valuation is expensive versus peers, with a 1.17 premium, while the expectations gap is modest and valuation is the main source of fragility. The evidence does not show a broader combination of expensive valuation, weak fundamentals, and turbulence, so the market setup is not described as fragile on all fronts.

What the fundamentals likely do

Recent financial performance is strong: global revenue rose from $192.6 million in 2025-Q4 to $240.3 million in 2026-Q2, and management has repeatedly raised 2026 revenue guidance. Near-term risk is still meaningful, with consecutive earnings misses and an elevated chance of another miss; continued BRIUMVI growth and progress on dosing changes remain key operating tests.

What TG Therapeutics, Inc. hinges on

The favorable case depends on BRIUMVI revenue growth continuing and management delivering on development plans, including the subcutaneous formulation, which could reach approval in 2028. The unfavorable case includes a guidance cut after recent increases, further earnings misses, or weaker jobs data that raises recession concerns; strength from healthcare bellwethers could support the sector backdrop.